Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q2 2021 · 10-Q
Revenue$24.36M$24.36M−43.2% vs Q2 2020 Net Income-$133.99M-$133.99MN/M vs Q2 2020 EPS Diluted-$1.45-$1.45N/M vs Q2 2020 Operating Income-$133,835,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$28,240,000N/M Margins · derivedOperating margin-549.3%−350.8 pt vs Q2 2020
Net margin-549.9%−351.0 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 9, 2021 · 40 d after period end